Akebia Therapeutics (AKBA) vs Lyell Immunopharma (LYEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lyell Immunopharma (LYEL) has outperformed Akebia Therapeutics (AKBA) over the past year, losing 51.9% versus a loss of 71.4%. Over five years, AKBA leads with a -71.4% price change compared with -96.7% for LYEL. Akebia Therapeutics is the larger company by market cap ($225.8 million vs $215.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | LYEL |
|---|---|---|
| Share price | $0.8148 | $8.79 |
| Market cap | $225.79M | $215.40M |
| 1-day change | -6.71% | +2.69% |
| YTD return | -49.39% | -71.44% |
| 1-year return | -71.41% | -51.86% |
| 5-year return | -71.41% | -96.69% |
| EPS (TTM) | $-0.12 | $-12.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $45.00 |
| 52-week low | $0.814 | $8.21 |
| Distance from 52-week high | -74.54% | -80.47% |
| Analyst consensus | none | buy |
| Avg. price target upside | +381.10% | +330.94% |
| Average volume | 6.18M | 145.70K |
| Shares outstanding | 277.11M | 24.51M |
| Employees | 194 | 161 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LYEL has outperformed AKBA by 19.5 percentage points over the past year.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About Lyell Immunopharma
LYEL stock →Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
AKBA vs LYEL FAQ
Which is bigger, Akebia Therapeutics or Lyell Immunopharma?
Akebia Therapeutics (AKBA) is larger, with a market capitalization of $225.79M compared with $215.40M for Lyell Immunopharma (LYEL).
Which stock has performed better over the past year, AKBA or LYEL?
LYEL returned -51.86% over the past 12 months, compared with -71.41% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and Lyell Immunopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.